Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kuano NOTUM inhibitor
- Development stage
- Preclinical
- Lead developer
- Kuano
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal
01
Overview
Kuano is developing a first-in-class small-molecule inhibitor of NOTUM for the treatment of colorectal cancer (CRC), including treatment-resistant forms. NOTUM is an enzyme (carboxylesterase) that negatively regulates the Wnt signaling pathway by deacylating Wnt ligands; this pathway is frequently dysregulated in CRC to drive tumor growth and therapy resistance. By inhibiting NOTUM, the drug candidate aims to modulate Wnt signaling and restore its normal function to overcome treatment resistance. The lead molecules were designed using Kuano's proprietary quantum simulation and artificial intelligence platform and have demonstrated in vivo efficacy in mouse models. As of 2024, the program is in preclinical development with planned progression to organoid-based studies.
- Other names
- NOTUM inhibitorsmall-molecule NOTUM inhibitor
02
Targets
NOTUM (Notum, palmitoleoyl-protein carboxylesterase)
Beyond the preview
Go deeper on Kuano NOTUM inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kuano NOTUM inhibitor.